There are more than a dozen treatment options for patients with relapsing multiple sclerosis and so far none for the progressive form. Why that is and what can be done to change that are two of the biggest challenges in the field today.
Some of the finest minds in the field of multiple sclerosis were in New Orleans for the annual ACTRIMS conference all looking to share their knowledge and learn more before returning home to their patients.
As researchers focus on finding treatments for progressive multiple sclerosis there are a number of potential angles to study to find the best treatment options possible. One potential area is the role of B cells in the treatment process.
As the first medication designed to treat primary progressive multiple sclerosis moves closer to the market there are still many questions about how effective it will be and what other treatment options may look like in the future.
Prior research has shown women suffering from multiple sclerosis (MS) often have a more benign initial course than male patients. However, these same female patients tend to quickly transition to secondary progressive disease as their approach menopause.